Peer reviewed
Retatrutide for Obesity: A Phase 2 Trial
Retatrutide phase 2 obesity trial (NEJM 2023): at 12 mg, mean body weight fell 17.5% at week 24 and 24.2% at week 48; GI adverse events were most common.
New England Journal of MedicinePublished Jun 26, 2023Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-retatrutide-phase2-2023- DOI
- 10.1056/NEJMoa2301972
Source usage
Linked from 12 pages
Compound
Retatrutide
Video auditUnapproved Weight-Loss Drug 'Reta' Sold Online Despite Safety Concerns
Video auditRetatrutide Masterclass: How To Use It Optimally (Dose, Frequency, Diet, Exercise, & Supplements)
Video auditDr. Explains Why Retatrutide is KING of Fat Loss Peptides
Video auditRetatrutide Masterclass (the 'how to' for EVERYTHING) - Dr Trevor Bachmeyer
Video auditSafety Concerns Over Doctors Prescribing an Experimental Weight-Loss Drug
Video auditNew Data Released on Weight-Loss Drug Retatrutide
Video auditCan Peptides Heal Your Joints, Gut, and Brain? Doctors Explain the Evidence
ComparisonRetatrutide vs Tirzepatide
Evidence curationBest Peptides for Weight Loss
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.